Weston, Massachusetts, United States Biogen Idec appeared to be the Corporate Investor, which was created in 1978. The main office of represented Corporate Investor is situated in the Weston. The venture was found in North America in United States.
Among the various public portfolio startups of the fund, we may underline Samsung Bioepis, Vivoryon Therapeutics, Neurimmune Holding The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most successful fund investment fields, there are Biopharma, Medical Device.
The current fund was established by Bernard Mach, Jeff Behrens, Phillip Sharp.
Considering the real fund results, this Corporate Investor is 12 percentage points more often commits exit comparing to other organizations. This Biogen Idec works on 28 percentage points more the average amount of lead investments comparing to the other organizations. The common things for fund are deals in the range of 50 - 100 millions dollars. The high activity for fund was in 2009. The fund is constantly included in less than 2 investment rounds annually. When the investment is from Biogen Idec the average startup value is more than 1 billion dollars. The top amount of exits for fund were in 2017.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Biogen Idec, startups are often financed by Warburg Pincus, Mayfield Fund, Abingworth. The meaningful sponsors for the fund in investment in the same round are SR One, U.S. Venture Partners (USVP), Partners HealthCare. In the next rounds fund is usually obtained by SR One, MPM Capital, Kleiner Perkins.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Azimuth Opportunity | New York, New York, United States |
| Bonnier | Stockholm, Stockholm County, Sweden |
| Brick & Mortar Ventures | California, San Francisco, United States |
| CFII | Beijing, Beijing, China |
| Government of Singapore | - |
| Iron Fund | Atlanta, Georgia, United States |
| L & T Property Investments | Allen Park, Michigan, United States |
| Lee Equity Partners | New York, New York, United States |
| Long Hill Capital | China, Shanghai |
| MediGene | Bayern, Germany, Martinsried |
| Nextblue | - |
| Ningbo Xuri Lamp Decoration | China, Xiangshan, Zhejiang |
| Rhineland-Palatinate Investment | - |
| Shanghai Jugu Equity Investment Fund | China, Shanghai |
| The Quercus Trust | - |
| Trans-Continental Venture Fund | India, Maharashtra, Worli |
| Upaya Social Ventures | Seattle, United States, Washington |
| Wicklow Capital | Chicago, Illinois, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Autobahn Therapeutics | $76M | 11 Jun 2020 | San Diego, California, United States | ||
Solid Biosciences | $50M | 30 Mar 2017 | Marlborough, Massachusetts, United States | ||
Rodin Therapeutics | $17M | 06 Jan 2016 | Cambridge, Massachusetts, United States | ||
True North Therapeutics | $22M | 17 Jun 2014 | South San Francisco, California, United States | ||
Ataxion | $17M | 17 Mar 2014 | Cambridge, Massachusetts, United States | ||
Knopp Biosciences | $30M | 03 Dec 2012 | Pittsburgh, Pennsylvania, United States | ||
iPierian | $29M | 09 Nov 2010 | South San Francisco, California, United States | ||
Virdante Pharmaceuticals | $30M | 25 Nov 2009 | Cambridge, Massachusetts, United States | ||
Intellikine | $51M | 22 Jul 2009 | San Diego, California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Autobahn Therapeutics | $76M | 11 Jun 2020 | San Diego, California, United States | ||
Solid Biosciences | $50M | 30 Mar 2017 | Marlborough, Massachusetts, United States | ||
Rodin Therapeutics | $17M | 06 Jan 2016 | Cambridge, Massachusetts, United States | ||
True North Therapeutics | $22M | 17 Jun 2014 | South San Francisco, California, United States | ||
Ataxion | $17M | 17 Mar 2014 | Cambridge, Massachusetts, United States | ||
Knopp Biosciences | $30M | 03 Dec 2012 | Pittsburgh, Pennsylvania, United States | ||
iPierian | $29M | 09 Nov 2010 | South San Francisco, California, United States | ||
Virdante Pharmaceuticals | $30M | 25 Nov 2009 | Cambridge, Massachusetts, United States | ||
Intellikine | $51M | 22 Jul 2009 | San Diego, California, United States |
